Sutro Biopharma Stock Market Value
| STRO Stock | USD 2.69 0.09 3.46% |
| Symbol | Sutro |
Sutro Biopharma Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sutro Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Revenue Per Share 2.253 | Quarterly Revenue Growth (0.50) | Return On Assets (0.18) | Return On Equity (1.11) |
The market value of Sutro Biopharma is measured differently than its book value, which is the value of Sutro that is recorded on the company's balance sheet. Investors also form their own opinion of Sutro Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sutro Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sutro Biopharma's market value can be influenced by many factors that don't directly affect Sutro Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sutro Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Sutro Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Sutro Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Sutro Biopharma.
| 09/30/2024 |
| 11/29/2024 |
If you would invest 0.00 in Sutro Biopharma on September 30, 2024 and sell it all today you would earn a total of 0.00 from holding Sutro Biopharma or generate 0.0% return on investment in Sutro Biopharma over 60 days. Sutro Biopharma is related to or competes with Cue Biopharma, Eliem Therapeutics, Inhibrx, and Molecular Partners. Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company More
Sutro Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Sutro Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Sutro Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 30.73 | |||
| Value At Risk | (8.71) | |||
| Potential Upside | 7.81 |
Sutro Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sutro Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Sutro Biopharma's standard deviation. In reality, there are many statistical measures that can use Sutro Biopharma historical prices to predict the future Sutro Biopharma's volatility.| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (1.05) | |||
| Total Risk Alpha | (1.52) | |||
| Treynor Ratio | (0.28) |
Sutro Biopharma Backtested Returns
Sutro Biopharma owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.12, which indicates the firm had a -0.12% return per unit of risk over the last 3 months. Sutro Biopharma exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Sutro Biopharma's Risk Adjusted Performance of (0.10), coefficient of variation of (694.87), and Variance of 26.23 to confirm the risk estimate we provide. The entity has a beta of 2.64, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sutro Biopharma will likely underperform. At this point, Sutro Biopharma has a negative expected return of -0.63%. Please make sure to validate Sutro Biopharma's value at risk and rate of daily change , to decide if Sutro Biopharma performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.09 |
Very weak reverse predictability
Sutro Biopharma has very weak reverse predictability. Overlapping area represents the amount of predictability between Sutro Biopharma time series from 30th of September 2024 to 30th of October 2024 and 30th of October 2024 to 29th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Sutro Biopharma price movement. The serial correlation of -0.09 indicates that less than 9.0% of current Sutro Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.09 | |
| Spearman Rank Test | -0.4 | |
| Residual Average | 0.0 | |
| Price Variance | 0.44 |
Sutro Biopharma lagged returns against current returns
Autocorrelation, which is Sutro Biopharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Sutro Biopharma's stock expected returns. We can calculate the autocorrelation of Sutro Biopharma returns to help us make a trade decision. For example, suppose you find that Sutro Biopharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Sutro Biopharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Sutro Biopharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Sutro Biopharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Sutro Biopharma stock over time.
Current vs Lagged Prices |
| Timeline |
Sutro Biopharma Lagged Returns
When evaluating Sutro Biopharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Sutro Biopharma stock have on its future price. Sutro Biopharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Sutro Biopharma autocorrelation shows the relationship between Sutro Biopharma stock current value and its past values and can show if there is a momentum factor associated with investing in Sutro Biopharma.
Regressed Prices |
| Timeline |
Pair Trading with Sutro Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sutro Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sutro Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Sutro Stock
| 0.63 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.52 | ESPR | Esperion Therapeutics | PairCorr |
| 0.51 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.46 | BHC | Bausch Health Companies | PairCorr |
| 0.43 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Sutro Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sutro Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sutro Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sutro Biopharma to buy it.
The correlation of Sutro Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sutro Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sutro Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sutro Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Sutro Biopharma Correlation, Sutro Biopharma Volatility and Sutro Biopharma Alpha and Beta module to complement your research on Sutro Biopharma. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Sutro Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.